BeOne Medicines (NASDAQ:ONC) Stock Price Expected to Rise, TD Cowen Analyst Says

BeOne Medicines (NASDAQ:ONC) had its target price increased by equities research analysts at TD Cowen from $424.00 to $454.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price target would suggest a potential upside of 30.36% from the stock’s previous close.

A number of other research analysts also recently commented on ONC. Barclays upped their price objective on shares of BeOne Medicines from $403.00 to $407.00 and gave the company an “overweight” rating in a research note on Thursday. Nomura raised BeOne Medicines to a “strong-buy” rating in a research report on Monday, July 27th. Truist Financial boosted their price objective on BeOne Medicines from $416.00 to $418.00 and gave the company a “buy” rating in a report on Thursday. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a report on Thursday. Finally, Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines has a consensus rating of “Moderate Buy” and an average price target of $400.00.

BeOne Medicines Stock Up 5.6%

Shares of NASDAQ:ONC opened at $348.27 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.27. The firm has a fifty day moving average price of $296.52 and a 200 day moving average price of $308.89. BeOne Medicines has a 1-year low of $253.95 and a 1-year high of $385.22. The stock has a market cap of $38.21 billion, a P/E ratio of 61.32 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. The firm had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. Sell-side analysts predict that BeOne Medicines will post 6.26 EPS for the current year.

Insider Transactions at BeOne Medicines

In other news, CEO John Oyler sold 145,861 shares of the firm’s stock in a transaction dated Tuesday, July 14th. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the transaction, the chief executive officer directly owned 8,122 shares of the company’s stock, valued at approximately $2,484,925.90. This trade represents a 94.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,484 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $269.37, for a total value of $399,745.08. Following the transaction, the chief operating officer owned 40 shares of the company’s stock, valued at $10,774.80. This represents a 97.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 345,561 shares of company stock worth $105,625,947 over the last quarter. 6.19% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Cetera Investment Advisers bought a new position in BeOne Medicines during the 2nd quarter worth about $455,000. Rhumbline Advisers bought a new position in BeOne Medicines during the 2nd quarter worth $275,000. Arrowstreet Capital Limited Partnership acquired a new position in BeOne Medicines in the 2nd quarter valued at $505,000. Invesco Ltd. acquired a new stake in BeOne Medicines in the second quarter valued at about $422,000. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of BeOne Medicines in the second quarter valued at approximately $68,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
• Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
• Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
• Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.